Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
PremiumPress ReleasesAyala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
6M ago
Advaxis Clarifies CMO Bonus Terms Amid Asset Sale
Premium
Company Announcements
Advaxis Clarifies CMO Bonus Terms Amid Asset Sale
7M ago
Advaxis Asset Sale Approved by Majority Shareholder Vote
Premium
Company Announcements
Advaxis Asset Sale Approved by Majority Shareholder Vote
7M ago
Advaxis Executives Secure Bonuses After Asset Purchase
PremiumCompany AnnouncementsAdvaxis Executives Secure Bonuses After Asset Purchase
8M ago
Advaxis Announces Definitive Agreement with Ayala Pharmaceuticals
Premium
Company Announcements
Advaxis Announces Definitive Agreement with Ayala Pharmaceuticals
8M ago
Immunome to acquire AL102 from Ayala for $20M in cash, $30M in stock
Premium
The Fly
Immunome to acquire AL102 from Ayala for $20M in cash, $30M in stock
8M ago
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
PremiumPress ReleasesAyala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
11M ago
Ayala Pharmaceuticals closes merger with Biosight
Premium
The Fly
Ayala Pharmaceuticals closes merger with Biosight
11M ago
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
Premium
Press Releases
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100